AU2021314977B2 - Combination therapy for inhalation administration - Google Patents

Combination therapy for inhalation administration Download PDF

Info

Publication number
AU2021314977B2
AU2021314977B2 AU2021314977A AU2021314977A AU2021314977B2 AU 2021314977 B2 AU2021314977 B2 AU 2021314977B2 AU 2021314977 A AU2021314977 A AU 2021314977A AU 2021314977 A AU2021314977 A AU 2021314977A AU 2021314977 B2 AU2021314977 B2 AU 2021314977B2
Authority
AU
Australia
Prior art keywords
solution composition
long
pharmaceutical solution
composition according
soft mist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021314977A
Other languages
English (en)
Other versions
AU2021314977A1 (en
Inventor
Laura Andrade Benitez
María MAESO PUERTOLLANO
Alejandro NIETO ORELLANA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Research SL
Original Assignee
Chemo Research SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72039503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2021314977(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chemo Research SL filed Critical Chemo Research SL
Publication of AU2021314977A1 publication Critical patent/AU2021314977A1/en
Application granted granted Critical
Publication of AU2021314977B2 publication Critical patent/AU2021314977B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021314977A 2020-07-31 2021-07-30 Combination therapy for inhalation administration Active AU2021314977B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382710.0 2020-07-31
EP20382710 2020-07-31
PCT/EP2021/071369 WO2022023515A1 (en) 2020-07-31 2021-07-30 Combination therapy for inhalation administration

Publications (2)

Publication Number Publication Date
AU2021314977A1 AU2021314977A1 (en) 2023-03-02
AU2021314977B2 true AU2021314977B2 (en) 2025-03-13

Family

ID=72039503

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021314977A Active AU2021314977B2 (en) 2020-07-31 2021-07-30 Combination therapy for inhalation administration

Country Status (13)

Country Link
US (1) US20230270754A1 (cg-RX-API-DMAC7.html)
EP (1) EP4188327B1 (cg-RX-API-DMAC7.html)
JP (1) JP7828949B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230052903A (cg-RX-API-DMAC7.html)
CN (1) CN115989032A (cg-RX-API-DMAC7.html)
AU (1) AU2021314977B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023001689A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186956A1 (cg-RX-API-DMAC7.html)
ES (1) ES3037198T3 (cg-RX-API-DMAC7.html)
FI (1) FI4188327T3 (cg-RX-API-DMAC7.html)
MX (1) MX2023001201A (cg-RX-API-DMAC7.html)
PL (1) PL4188327T3 (cg-RX-API-DMAC7.html)
WO (1) WO2022023515A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4188327B1 (en) 2020-07-31 2025-05-28 Chemo Research, S.L. Combination therapy for inhalation administration
WO2026057872A1 (en) * 2024-09-16 2026-03-19 Invox Belgium Nv Inhalable compositions
CN121714579A (zh) * 2026-02-25 2026-03-24 上海臣邦医药科技股份有限公司 一种三联复方吸入制剂的药物组合物及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181478A1 (en) * 2000-10-31 2003-09-25 Boehringer Ingelheim Pharma Kg Inhalable formulation of a solution containing a tiotropium salt
US20060127322A1 (en) * 1995-06-27 2006-06-15 Boehringer Ingelheim Kg Stable pharmaceutical Budesonide preparation for producing propellant-free aerosols
EP3151812A1 (en) * 2014-06-09 2017-04-12 Chiesi Farmaceutici S.p.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
WO2017089404A1 (en) * 2015-11-25 2017-06-01 Jagotec Ag Pharmaceutical composition

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851317A (en) 1987-11-04 1989-07-25 E. I. Du Pont De Nemours And Company Laminar flow toning station having conductive and nonconductive elements therein
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
DE19653969A1 (de) 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
DK1121112T3 (da) * 1998-10-17 2002-09-16 Boehringer Ingelheim Pharma Lagringsdygtigt koncentrat af aktivt stof med formoterol
EE05167B1 (et) 2000-05-22 2009-06-15 Chiesi Farmaceutici S.P.A. Stabiilsed farmatseutilised lahuspreparaadid survestatud doseerivatele inhalaatoritele
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
CA2733294C (en) 2000-10-31 2011-12-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical combination of a tiotropium salt and ciclesonide
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
EP1879571A1 (de) 2005-04-23 2008-01-23 Boehringer Ingelheim International GmbH Arzneimittelkombination für die inhalation enthaltend neben einem anticholinergikum ein betamimetikum und ein steroid
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
US20070293460A1 (en) 2005-10-31 2007-12-20 Richie's Pharmacy And Medical Supply, Incorporated Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease
US20070098644A1 (en) 2005-10-31 2007-05-03 Richie's Pharmacy And Medical Supply, Incorporated Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease
DE102006023756A1 (de) 2006-05-20 2007-11-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ethanolhaltige Aerosolformulierung für die Inhalation
UY30542A1 (es) 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
HRP20140582T4 (hr) 2009-12-23 2023-06-09 Chiesi Farmaceutici S.P.A. Kombinacijska terapija za copd
WO2011076841A2 (en) 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Combination therapy for copd
SG181870A1 (en) 2009-12-23 2012-07-30 Chiesi Farma Spa Aerosol formulation for copd
US20120220557A1 (en) 2011-02-17 2012-08-30 Chiesi Farmaceutici S.P.A. Liquid propellant-free formulation comprising an antimuscarinic drug
HRP20181980T1 (hr) 2012-12-21 2019-01-25 Boehringer Ingelheim Vetmedica Gmbh Ciklezonid za liječenje dišnih puteva kod konja
JP6534397B2 (ja) 2013-12-30 2019-06-26 シエシー ファルマセウティチィ ソシエタ ペル アチオニ グリコピロニウム臭化物およびホルモテロールの組合せの安定な加圧エアゾール溶液組成物
AU2014375301C1 (en) * 2013-12-30 2026-02-19 Chiesi Farmaceutici S.P.A. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
WO2015193213A1 (en) 2014-06-18 2015-12-23 Boehringer Ingelheim Vetmedica Gmbh Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
WO2020167893A1 (en) 2019-02-13 2020-08-20 Molecular Infusions, Llc Methods for non-irritating pulmonary administration of cannabinoids using soft mist inhalers
EP4188327B1 (en) 2020-07-31 2025-05-28 Chemo Research, S.L. Combination therapy for inhalation administration

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060127322A1 (en) * 1995-06-27 2006-06-15 Boehringer Ingelheim Kg Stable pharmaceutical Budesonide preparation for producing propellant-free aerosols
US20030181478A1 (en) * 2000-10-31 2003-09-25 Boehringer Ingelheim Pharma Kg Inhalable formulation of a solution containing a tiotropium salt
EP3151812A1 (en) * 2014-06-09 2017-04-12 Chiesi Farmaceutici S.p.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
WO2017089404A1 (en) * 2015-11-25 2017-06-01 Jagotec Ag Pharmaceutical composition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NEWMAN, S.P. et al. "Efficient Delivery to the Lungs of Flunisolide Aerosol From a New Portable Hand-Held Multidose Nebulizer", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 85, no. 9, (1996) pages 960-964 *
PITCAIRN G. et al. JOURNAL OF AEROSOL MEDICINE, vol. 18, no. 3 (2005) pages 264-272 *

Also Published As

Publication number Publication date
CA3186956A1 (en) 2022-02-03
PL4188327T3 (pl) 2025-09-01
US20230270754A1 (en) 2023-08-31
MX2023001201A (es) 2023-05-03
FI4188327T3 (fi) 2025-07-25
JP7828949B2 (ja) 2026-03-12
BR112023001689A2 (pt) 2023-05-02
WO2022023515A1 (en) 2022-02-03
JP2023540171A (ja) 2023-09-22
EP4188327B1 (en) 2025-05-28
CN115989032A (zh) 2023-04-18
ES3037198T3 (en) 2025-09-30
AU2021314977A1 (en) 2023-03-02
KR20230052903A (ko) 2023-04-20
EP4188327A1 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
US11213485B2 (en) Pharmaceutical solution formulations for pressurized metered dose inhalers
RU2327450C2 (ru) Фармацевтические продукты и композиции, содержащие специфические антихолинергические средства, агонисты бета-2 и кортикостероиды
US8313732B2 (en) Formoterol superfine formulation
US20070065366A1 (en) Pharmaceutical formulations comprising a long-acting beta2-agonist for administration by nebulisation
CN103052378A (zh) 包含磷酸二酯酶抑制剂的药物制剂
EP4188327B1 (en) Combination therapy for inhalation administration
EP2999460A1 (en) Compositions, methods&systems for respiratory delivery of three or more active agents
US20260069601A1 (en) Pharmaceutical composition for inhalation for preventing or treating respiratory disease
EP1415647A1 (en) "Long-acting beta-2 agonists ultrafine formulations"
CN115397417A (zh) 含有噻托溴铵和奥达特罗的可吸入溶液制剂
WO2020141472A1 (en) Nebulization composition comprising tiotropium and indacaterol
HK1228751A1 (en) Pharmaceutical solution formulations for pressurised metered dose inhalers
HK1228758A1 (en) Pharmaceutical solution formulations for pressurised metered dose inhalers
HK1181310A (en) Pharmaceutical solution formulations for pressurised metered dose inhalers
HK1128615A (en) Pharmaceutical solution formulations for pressurised metered dose inhalers
HK1118473A (en) Pharmaceutical formulations comprising a long-acting beta2-agonist for administration by nebulisation

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)